Jasper Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $19.0M
- Price
- $0.5697
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.71%
- Volume
- 365.5K
About
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Quick stats
Shares outstanding33.3M
Computed float27.0M
Float / shares81.2%
Cash runway (months)56.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001788028
Websitehttps://jaspertx.com
AI Summary
AI-generated1/8
minorneutralother
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics commenced a tender offer to purchase any and all of the warrants issued in its September 18, 2025 public offering at $0.324 in cash per warrant.
The offer expires one minute after 11:59 p.m. ET on November 6, 2026, and if all 12,345,707 outstanding warrants are tendered, the company would pay approximately $4.0 million from cash on hand.
The stated purpose is to reduce potential dilution from warrants with a $2.92 exercise price, giving shareholders greater certainty on the capital structure.
Red flags
- up to $4.0 million of cash deployed to retire warrants for a clinical-stage biotech with stated capital-raising risks
- warrants not tendered remain outstanding and exercisable at $2.92 through March 2030